Colorectal Cancer Drugs and Pipeline Analysis 2025: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, Route of Administration, and Companies by DelveInsight

(Albany, United States) "Colorectal Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Colorectal Cancer Market.

Colorectal Cancer pipeline constitutes 195+ key companies continuously working towards developing 200+ Colorectal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Colorectal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The colorectal cancer pipeline product analysis report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Colorectal Cancer Pipeline Report:
• Colorectal Cancer Companies across the globe are diligently working toward developing novel Colorectal Cancer treatment therapies with a considerable amount of success over the years.
• Leading Colorectal Cancer companies working in the treatment market are Plus Therapeutics, Processa Pharmaceutic als, Shanghai Henlius Biotech, Apollomics, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmace uticals Co., Ltd., G1 Therapeutics, Amgen, Mirati Therapeutics, and others, are developing therapies for the Colorectal Cancer treatment
• Emerging Colorectal Cancer therapies in the different phases of clinical trials are- 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR, 255, Evorpacept (ALX148), CPGJ 602 Sunshine, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, Lumakras (sotorasib), MRTX849, and others are expected to have a significant impact on the Colorectal Cancer market in the coming years.
• On March 27, 2025, LIXTE Biotechnology Holdings provided an update on its recent activities. The Company announced that the first patient had been dosed in a new clinical trial conducted in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. ("Roche") for the treatment of unresponsive (MSI Low) metastatic colorectal cancer.
• On January 25, 2025, Exelixis announced results from an expansion cohort of the Phase Ib/II STELLAR-001 trial that evaluated zanzalintinib alone or in combination with atezolizumab (Tecentriq) in patients with previously treated metastatic colorectal cancer. The findings were presented during Poster Session C: Cancers of the Colon, and Anus, at 7:00 a.m. PT on January 25 at the American Society of Clinical Oncology 2025 Gastrointestinal Cancers Symposium (ASCO GI 2025).
• In January 2025, Marengo Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to invikafusp alfa (STAR0602), Marengo's first-in-class selective dual T cell agonist being studied as a potential new treatment for advanced colorectal cancer with TMB-H.
• In January 2025, Mirror Biologics announced that it had entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany. The parties will collaborate to conduct a Phase II clinical trial to evaluate the combination of an experimental immunotherapy drug, AlloStim from Mirror, and an immune checkpoint inhibitor (ICI), avelumab (BAVENCIO) from Merck KGaA, Darmstadt, Germany, in fourth-line metastatic colorectal cancer.
• On January 16, 2025, the Food and Drug Administration approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
• In December 2024, Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.i The indication was approved based on a statistically significant and clinically meaningful improvement in response rate and durability of response in treatment-naïve patients treated with BRAFTOVI in combination with cetuximab and mFOLFOX6 from the Phase 3 BREAKWATER trial. Continued approval for this indication is contingent upon verification of clinical benefit. This accelerated approval is among the first in the industry to be conducted under the FDA's Project FrontRunner, which seeks to support the development and approval of new cancer drugs for advanced or metastatic disease.
• In September 2024, FRUZAQLA® (fruquintinib) is a kinase inhibitor approved for treating adults with metastatic colorectal cancer (mCRC). This novel oral targeted therapy is designed for once-daily use, providing a non-chemotherapy alternative for patients who have previously received treatments such as fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, along with anti-vascular endothelial growth factor (VEGF) therapy.
• In January 2024, Bristol Myers Squibb (BMS) recently disclosed encouraging findings from the Phase III CheckMate -8HW study involving Opdivo (nivolumab) and Yervoy (ipilimumab) as an initial treatment choice for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). This open-label, randomized Phase III trial aims to assess the effectiveness of combining Opdivo and Yervoy compared to the chemotherapy selected by the investigator.
• On November 8, 2023, the FDA approved fruquintinib (brand name Fruzaqla) for adult patients with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

Colorectal Cancer Overview
Colorectal cancer (CRC) is a common malignancy that develops in the colon, often beginning as benign growths called polyps. Over time, some polyps can become cancerous, emphasizing the importance of early detection and intervention. CRC is the third most common cancer worldwide and a leading cause of cancer-related deaths.
Risk factors for Colorectal cancer include age (typically over 50), family history of the disease, genetic conditions such as Lynch syndrome, inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis), a diet high in red or processed meats, obesity, smoking, and sedentary lifestyle. Symptoms may include changes in bowel habits, rectal bleeding, abdominal pain, unexplained weight loss, and fatigue. In some cases, CRC may be asymptomatic until it reaches advanced stages.
Colorectal cancer Diagnosis involves a combination of colonoscopy, imaging studies (CT or MRI), and biopsy to confirm malignancy. Screening tests, such as fecal occult blood testing or stool DNA tests, can aid in early detection.
Colorectal cancer Treatment depends on the stage of the cancer. Colorectal cancer Surgery is often the primary treatment for localized tumors, while chemotherapy, radiation, and targeted therapies are used for advanced or metastatic cases. Immunotherapy is emerging as a promising option for certain genetic subtypes of Colorectal cancer. Early detection significantly improves survival rates.

Get a Free Sample PDF Report to know more about Colorectal Cancer Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Colorectal Cancer Drugs Under Different Phases of Clinical Development Include:
• 188RNL-BAM: Plus Therapeutics
• PCS11T: Processa Pharmaceutic als
• HLX13: Shanghai Henlius Biotech
• Adagrasib: Mirati Therapeutics
• XL092: Exelixis
• EO2040: Enterome
• Etrumadenant: Arcus Biosciences
• LYL845: Lyell Immunopharma
• Geptanolimab: Apollomics
• HDM201: Novartis Pharmaceuticals
• TP-1454: Sumitomo Pharma Oncology
• NT219: Purple Biotech Ltd.
• NKTR-255: Nektar Therapeutics
• Evorpacept (ALX148): ALX Oncology Inc.
• CPGJ 602 Sunshine: Guojian Pharmaceutical
• Trastuzumab deruxtecan: Daiichi Sankyo
• GRT-C901: Gritstone Bio, Inc
• SHR-1701: Suzhou Suncadia Biopharmace uticals Co., Ltd.
• Trilaciclib: G1 Therapeutics
• Lumakras (sotorasib): Amgen
• MRTX849: Mirati Therapeutics

Route of Administration
Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Colorectal Cancer Pipeline Therapeutics Assessment
• Colorectal Cancer Assessment by Product Type
• Colorectal Cancer By Stage and Product Type
• Colorectal Cancer Assessment by Route of Administration
• Colorectal Cancer By Stage and Route of Administration
• Colorectal Cancer Assessment by Molecule Type
• Colorectal Cancer by Stage and Molecule Type

DelveInsight's Colorectal Cancer Report covers around 200+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Colorectal Cancer product details are provided in the report. Download the Colorectal Cancer pipeline report to learn more about the emerging Colorectal Cancer therapies - https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Colorectal Cancer Therapeutics Market include:
Key companies developing therapies for Colorectal Cancer are - Plus Therapeutics, Processa Pharmaceutic als, Shanghai Henlius Biotech, Apollomics, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmace uticals Co., Ltd., G1 Therapeutics, Amgen, Mirati Therapeutics, and others.

Colorectal Cancer Pipeline Analysis:
The Colorectal Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Colorectal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Colorectal Cancer Treatment.
• Colorectal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, molecular type and colorectal cancer pipeline product analysis.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Colorectal Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Colorectal Cancer drugs and therapies - https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Colorectal Cancer Pipeline Market Drivers
Emergence of targeted therapies for mCRC treatment, technical Advancement in molecular subtyping of CRC tumors, increase in product development activities are some of the important factors that are fueling the Colorectal Cancer Market.

Colorectal Cancer Pipeline Market Barriers
However, limitations in understanding secondary resistance, high Cost of Treatment
Challenges related to precision oncology in mCRC management and other factors are creating obstacles in the Colorectal Cancer Market growth.

Scope of Colorectal Cancer Pipeline Drug Insight
• Coverage: Global
• Key Colorectal Cancer Companies: Plus Therapeutics (PSTV: NASDAQ), Processa Pharmaceuticals (PCSA: NASDAQ), Shanghai Henlius Biotech (2696: HKEX), Apollomics (APLM: NASDAQ), Novartis Pharmaceuticals (NVS: NYSE), Sumitomo Pharma Oncology (4506: TYO), Purple Biotech Ltd. (PPBT: NASDAQ), Nektar Therapeutics (NKTR: NASDAQ), ALX Oncology Inc. (ALXO: NASDAQ), Daiichi Sankyo (4568: TYO), Gritstone Bio, Inc. (GRTS: NASDAQ), G1 Therapeutics (GTHX: NASDAQ), Amgen (AMGN: NASDAQ), Mirati Therapeutics (MRTX: NASDAQ), and others.
• Key Colorectal Cancer Therapies: 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR, 255, Evorpacept (ALX148), CPGJ 602 Sunshine, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, Lumakras (sotorasib), MRTX849, and others
• Colorectal Cancer Therapeutic Assessment: Colorectal Cancer current marketed and Colorectal Cancer emerging therapies
• Colorectal Cancer Market Dynamics: Colorectal Cancer market drivers and Colorectal Cancer market barriers

Request for Sample PDF Report for Colorectal Cancer Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Colorectal Cancer Report Introduction
2. Colorectal Cancer Executive Summary
3. Colorectal Cancer Overview
4. Colorectal Cancer- Analytical Perspective In-depth Commercial Assessment
5. Colorectal Cancer Pipeline Therapeutics
6. Colorectal Cancer Late Stage Products (Phase II/III)
7. Colorectal Cancer Mid Stage Products (Phase II)
8. Colorectal Cancer Early Stage Products (Phase I)
9. Colorectal Cancer Preclinical Stage Products
10. Colorectal Cancer Therapeutics Assessment
11. Colorectal Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Colorectal Cancer Key Companies
14. Colorectal Cancer Key Products
15. Colorectal Cancer Unmet Needs
16 . Colorectal Cancer Market Drivers and Barriers
17. Colorectal Cancer Future Perspectives and Conclusion
18. Colorectal Cancer Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/ats-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.